Fig. 4From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphomaExponential TFI curves used in model base case. KM, Kaplan–Meier; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone; TFI, treatment-free interval; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisoneBack to article page